The Trilomer⢠platform of peptidomimetic binders offered by Trilo Therapeutics allows for the targeted inhibition of disease-causing proteins, for the treatment of cancer, autoimmune diseases, infectious diseases, and others. In a revolution of therapeutic approaches, Trilomer⢠peptidomimetic binders combine the cell permeability and degradation resistance of small molecules with the large surface area of antibodies, allowing them to target either intracellular and extracellular targets. Due to their fully synthetic modular building blocks, affinity optimization and structure-activity relationships (SAR) can be performed much more rapidly than either traditional medicinal chemistry or targeted mutagenesis of biologi
